Eli Lilly and Company $LLY Shares Acquired by UNIVEST FINANCIAL Corp

UNIVEST FINANCIAL Corp increased its position in Eli Lilly and Company (NYSE:LLY) by 24.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 34,297 shares of the company’s stock after buying an additional 6,678 shares during the quarter. Eli Lilly and Company comprises about 1.5% of UNIVEST FINANCIAL Corp’s investment portfolio, making the stock its 14th biggest position. UNIVEST FINANCIAL Corp’s holdings in Eli Lilly and Company were worth $26,169,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Sumitomo Mitsui Financial Group Inc. acquired a new position in Eli Lilly and Company during the second quarter valued at approximately $27,000. Evolution Wealth Management Inc. purchased a new position in Eli Lilly and Company in the 2nd quarter valued at about $29,000. Steph & Co. increased its stake in shares of Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after buying an additional 29 shares during the last quarter. Financial Gravity Companies Inc. acquired a new position in Eli Lilly and Company in the second quarter worth about $31,000. Finally, Bare Financial Services Inc increased its holdings in Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 29 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on LLY shares. Morgan Stanley increased their target price on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a report on Monday, November 24th. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Scotiabank initiated coverage on shares of Eli Lilly and Company in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 target price for the company. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Finally, CICC Research lifted their price target on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a report on Thursday, November 13th. Four research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $1,174.61.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA granted Breakthrough Therapy designation for Lilly’s ovarian cancer candidate (sofetabart/mipitecan), improving the odds of faster development and a premium approval pathway for a novel oncology asset. Lilly receives FDA’s breakthrough therapy designation for ovarian cancer drug
• Positive Sentiment: Lilly launched a Phase 3b dosing study for retatrutide (obesity candidate), a near-term program de‑risk step that could support label expansion and broaden commercial use if results are favorable. Eli Lilly Advances Retatrutide With New Phase 3b Obesity Dosing Study
• Positive Sentiment: Data/real‑world studies continue to support obesity and metabolic franchises: SURMOUNT‑REAL UK (tirzepatide real‑world) updates and a retatrutide osteoarthritis signal suggest incremental clinical and commercial benefits beyond weight loss. These help underpin revenue upside for GLP/GIP drugs. Lilly’s SURMOUNT-REAL UK Trial: Real-World Test of Tirzepatide’s Obesity Upside
• Positive Sentiment: Lilly expanded its oncology imaging footprint with a new Phase 1 PET tracer study, signaling diversification into diagnostics/precision oncology that can boost long‑term margins and pipeline value. Eli Lilly Expands Oncology Imaging Footprint With New Phase 1 PET Tracer Study
• Positive Sentiment: Executives at the JPMorgan Healthcare Conference reiterated that the obesity market will evolve to include more pill options, combos and better access — a structural message that supports multi‑year demand growth for Lilly’s metabolic portfolio. What obesity drugmakers see next in the market: More pills, easier access and drug combinations
• Neutral Sentiment: Lilly confirmed its fourth‑quarter 2025 earnings release and conference call for Feb. 4 — a scheduled event that will likely drive near‑term volatility as investors re‑assess guidance and sales cadence. Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
• Neutral Sentiment: Organizational update: Lilly appointed Pranav Shroff as director of marketing — a routine personnel move with limited near‑term financial impact but relevant for commercial execution. Eli Lilly appoints Pranav Shroff as director of marketing
• Negative Sentiment: Competition risk in key international markets: Sun Pharma won approval for a Wegovy generic in India, intensifying price and market‑share pressure in a top growth region and foreshadowing similar generic/biologic competition scenarios. Eli Lilly, Novo Nordisk Set for Fierce Battle in India’s Obesity Drug Market as Sun Pharma Wins Wegovy Generic Nod
• Negative Sentiment: Legal/political overhang: coverage cites a lawsuit and public scrutiny over insulin pricing that can bring reputational and financial risk if litigation expands or results in penalties. Rokita Discusses Lawsuit Against Eli Lilly & Insulin Prices

Eli Lilly and Company Price Performance

NYSE LLY opened at $1,087.63 on Friday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The stock has a market cap of $1.03 trillion, a price-to-earnings ratio of 53.21, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35. The company has a 50-day moving average price of $1,056.39 and a two-hundred day moving average price of $878.04.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.